Bio-Path Holdings Inc (BPTH):企業の財務・戦略的SWOT分析

◆英語タイトル:Bio-Path Holdings Inc (BPTH) - Financial and Strategic SWOT Analysis Review
◆商品コード:DATA904C15063
◆発行会社(調査会社):GlobalData
◆発行日:2019年3月
◆ページ数:25
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD300 ⇒換算¥39,900見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD600 ⇒換算¥79,800見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD900 ⇒換算¥119,700見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Bio-Path Holdings Inc (Bio-Path) is a clinical stage biotechnology company that develops targeted therapies for acute myeloid leukemia (AML), chronic myeloid leukemia (CML) and other challenging cancers. The company provides products pipeline such as prexigebersen (Liposomal Grb2 Antisense) and BP1002 (Liposomal Bcl2). Its prexigebersen (Liposomal Grb2 Antisense), is developed for the treatment of Acute Myeloid Leukemia (AML) and solid tumors. Bio-Path’s BP1002 (Liposomal Bcl2) is used for the treatment of lymphoma, leukemia, colon, prostate and breast cancers. The company’s proprietary liposomal delivery and antisense technology platform DNAbilize, is used to systemically distribute nucleic acid drugs throughout the human body with a simple intravenous transfusion. Bio-Path is headquartered in Bellaire, Texas, the US.

Bio-Path Holdings Inc Key Recent Developments

Nov 15,2018: Bio-Path Holdings Reports Third Quarter 2018 Financial Results
Nov 08,2018: Bio-Path Holdings to Announce Third Quarter 2018 Financial Results on November 15, 2018
Aug 16,2018: Bio-Path Holdings Appoints Dr. Jason B. Fleming to Scientific Advisory Board
Aug 15,2018: Bio-Path Holdings announces second quarter 2018 financial results
May 16,2018: Bio-Path Holdings Reports First Quarter 2018 Financial Results

This comprehensive SWOT profile of Bio-Path Holdings Inc provides you an in-depth strategic analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

This company report forms part of GlobalData’s ‘Profile on Demand’ service, covering over 50,000 of the world’s leading companies. Once purchased, GlobalData’s highly qualified team of company analysts will comprehensively research and author a full financial and strategic analysis of Bio-Path Holdings Inc including a detailed SWOT analysis, and deliver this direct to you in pdf format within two business days. (excluding weekends).

The profile contains critical company information including*,

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Note*: Some sections may be missing if data is unavailable for the company.

Key benefits of buying this profile include,

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

【レポートの目次】

Table of Contents

Section 1 – About the Company

Bio-Path Holdings Inc – Key Information
Bio-Path Holdings Inc – Overview
Bio-Path Holdings Inc – Key Employees
Bio-Path Holdings Inc – Key Employee Biographies
Bio-Path Holdings Inc – Key Operational Heads
Bio-Path Holdings Inc – Major Products and Services
Bio-Path Holdings Inc – History
Bio-Path Holdings Inc – Company Statement
Bio-Path Holdings Inc – Locations And Subsidiaries
Bio-Path Holdings Inc – Key Manufacturing facilities
Head Office
Other Locations & Subsidiaries

Section 2 – Company Analysis

Bio-Path Holdings Inc – Business Description
Bio-Path Holdings Inc – Corporate Strategy
Bio-Path Holdings Inc – SWOT Analysis
SWOT Analysis – Overview
Bio-Path Holdings Inc – Strengths
Bio-Path Holdings Inc – Weaknesses
Bio-Path Holdings Inc – Opportunities
Bio-Path Holdings Inc – Threats
Bio-Path Holdings Inc – Key Competitors

Section 3 – Company Financial Performance Charts

Bio-Path Holdings Inc – Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts

Section 4 – Appendix

Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

Note*: Some sections may be missing if data is unavailable for the company

List of Tables

Bio-Path Holdings Inc, Key Information
Bio-Path Holdings Inc, Key Ratios
Bio-Path Holdings Inc, Share Data
Bio-Path Holdings Inc, Major Products and Services
Bio-Path Holdings Inc, History
Bio-Path Holdings Inc, Key Employees
Bio-Path Holdings Inc, Key Employee Biographies
Bio-Path Holdings Inc, Key Operational Heads
Bio-Path Holdings Inc, Other Locations
Bio-Path Holdings Inc, Subsidiaries
Bio-Path Holdings Inc, Key Manufacturing facilities
Bio-Path Holdings Inc, Key Competitors
Bio-Path Holdings Inc, SWOT Analysis
Bio-Path Holdings Inc, Ratios based on current share price
Bio-Path Holdings Inc, Annual Ratios
Bio-Path Holdings Inc, Interim Ratios
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures

Bio-Path Holdings Inc, Performance Chart
Bio-Path Holdings Inc, Ratio Charts

★海外企業調査レポート[Bio-Path Holdings Inc (BPTH):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Nihon Kohden Corporation:戦略・SWOT・企業財務分析
    Nihon Kohden Corporation - Strategy, SWOT and Corporate Finance Report Summary Nihon Kohden Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Richter Gedeon Nyrt (RICHTER):医療機器:M&Aディール及び事業提携情報
    Summary Richter Gedeon Nyrt (Richter) is a pharmaceutical company that develops, manufactures and commercializes a wide range of drugs including original, generic and licensed products and over-the-counter (OTC) medicines. The company’s product portfolio encompasses medicines to treat gynaecological …
  • Gartner, Inc.:企業の戦略・SWOT・財務情報
    Gartner, Inc. - Strategy, SWOT and Corporate Finance Report Summary Gartner, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • SeaBird Exploration PLC (SBX):石油・ガス:M&Aディール及び事業提携情報
    Summary SeaBird Exploration PLC (SeaBird) is an oil and gas company that offers marine seismic data services. The company’s services include 2D seismic acquisition, 3D and 3D shallow water acquisition and source vessel. Its source vessels offers services such as conventional undershoots, 4d repeat s …
  • Aptuit LLC-製薬・医療分野:企業M&A・提携分析
    Summary Aptuit LLC (Aptuit) is a provider of drug discovery and development services. The company offer wide range of services such as manufacturing, project management, small and large molecules analysis, formulation development, integrated chemistry, API route scouting and process development, con …
  • Dawnbreaker, Inc.:企業の戦略・SWOT・財務分析
    Dawnbreaker, Inc. - Strategy, SWOT and Corporate Finance Report Summary Dawnbreaker, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Northern Minerals Ltd (GPP):企業の財務・戦略的SWOT分析
    Summary Northern Minerals Ltd (Northern Minerals) formerly known as Greenpower Energy Limited, is a mining, exploration and development company. The company’s business activities include acquisition, exploration, and development of petroleum, mineral and hydrothermal exploration properties. It explo …
  • Teijin Ltd (3401)-製薬・医療分野:企業M&A・提携分析
    Summary Teijin Ltd (Teijin) is a technology driven holding company offering solutions in the areas of information and electronics, healthcare, environment and energy and safety and protection. It focuses on the manufacture and sale of aramid fiber, carbon fiber products, synthetic fiber, films, poly …
  • Cipla Ltd (CIPLA):製薬・医療:M&Aディール及び事業提携情報
    Summary Cipla Ltd (Cipla) is a pharmaceutical company, which manufactures and distributes branded medicines, generics and active pharmaceutical ingredients (APIs). It offers products for the treatment of various conditions such as cardiovascular and pediatric diseases, dermatological and cosmetologi …
  • Amil Assistencia Medica Internacional S/A:企業の戦略・SWOT・財務情報
    Amil Assistencia Medica Internacional S/A - Strategy, SWOT and Corporate Finance Report Summary Amil Assistencia Medica Internacional S/A - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SW …
  • Excision BioTherapeutics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Excision BioTherapeutics Inc (Excision BioTherapeutics) is a developer of gene editing therapeutics for the treatment of infectious diseases. The company’s products comprise EBT101, a HIV CRISPR Cas9 gRNA multiplex biologic for the prevention of Human Immunodeficiency Virus; EBT103, a PML JC …
  • Enterprise Rent-A-Car Company:企業の戦略・SWOT・財務情報
    Enterprise Rent-A-Car Company - Strategy, SWOT and Corporate Finance Report Summary Enterprise Rent-A-Car Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • North Asia Strategic Holdings Limited:企業の戦略・SWOT・財務情報
    North Asia Strategic Holdings Limited - Strategy, SWOT and Corporate Finance Report Summary North Asia Strategic Holdings Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analy …
  • First Busey Corp:企業の戦略・SWOT・財務情報
    First Busey Corp - Strategy, SWOT and Corporate Finance Report Summary First Busey Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Hemispherx Biopharma Inc (HEB):医療機器:M&Aディール及び事業提携情報
    Summary Hemispherx Biopharma Inc (Hemispherx) is a biopharmaceutical company, which develops, manufactures and commercializes drug therapies for the treatments of viral and immune based chronic disorders. It offers products for the treatment of various diseases such as hepatitis B, hepatitis C, chro …
  • Ergon Energy Corporation Limited:企業の戦略・SWOT・財務分析
    Ergon Energy Corporation Limited - Strategy, SWOT and Corporate Finance Report Summary Ergon Energy Corporation Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • VytronUS Inc:医療機器:M&Aディール及び事業提携情報
    Summary VytronUS Inc (VytronUS), formerly CardionUS Inc, is an independent clinical stage medical device company that develops technologies for the treatment atrial fibrillation and other cardiac arrhythmias. The company is developing a catheter-based imaging and ablation platform based on low-inten …
  • Lidco Group Plc (LID):企業の製品パイプライン分析
    Summary Lidco Group Plc (LiDCO) is a medical device company that supplies hemodynamic monitoring equipment. The company's product portfolio include LiDCOrapid, LiDCOunity, LiDCOplus, LiDCOview and LiDCOaccessories . Its LiDCOplus is a computer-based platform monitor, which is used in the intensive c …
  • Enel Generacion Chile SA:企業の発電所・SWOT分析2018
    Enel Generacion Chile SA - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key empl …
  • Hasbro Inc (HAS):企業の財務・戦略的SWOT分析
    Hasbro Inc (HAS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆